MX2019007411A - Reuso de enzimas en glucomanipulacion in vitro de anticuerpos. - Google Patents

Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.

Info

Publication number
MX2019007411A
MX2019007411A MX2019007411A MX2019007411A MX2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A
Authority
MX
Mexico
Prior art keywords
enzymes
region
antibody
glycosylation
antibodies
Prior art date
Application number
MX2019007411A
Other languages
English (en)
Inventor
Falkenstein Roberto
Walch Heiko
Malik Sebastian
Thomann Marco
Grunert Ingrid
Freiherr Von Roman Matthias
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019007411A publication Critical patent/MX2019007411A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

En la presente descripción se informa de un método para la preparación/producción enzimática de un anticuerpo con una glucosilación modificada en la región Fc que comprende las etapas de incubar un anticuerpo que presenta una glucosilación en la región Fc con uno o más enzimas durante un tiempo suficiente y bajo condiciones adecuadas para modificar la glucosilación de la región Fc hasta una forma definida, separar en una o más etapas cromatográficas el anticuerpo con una glucosilación modificada en la región Fc respecto del enzima o enzimas y producir de esta manera el anticuerpo con una glucosilación modificada en la región Fc y uno o más enzimas reciclados y repetir la etapa de incubación con uno o más enzimas reciclados por lo menos una vez.
MX2019007411A 2016-12-21 2017-12-19 Reuso de enzimas en glucomanipulacion in vitro de anticuerpos. MX2019007411A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16205586 2016-12-21
EP17157005 2017-02-20
PCT/EP2017/083430 WO2018114878A1 (en) 2016-12-21 2017-12-19 Re-use of enzymes in in vitro glycoengineering of antibodies

Publications (1)

Publication Number Publication Date
MX2019007411A true MX2019007411A (es) 2019-08-29

Family

ID=61094375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007411A MX2019007411A (es) 2016-12-21 2017-12-19 Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.

Country Status (12)

Country Link
US (1) US20200165321A1 (es)
EP (1) EP3559250A1 (es)
JP (1) JP6931058B2 (es)
KR (1) KR102390246B1 (es)
CN (1) CN110100007B (es)
AU (1) AU2017381656B2 (es)
BR (1) BR112019009839A2 (es)
CA (1) CA3043158A1 (es)
IL (1) IL267349A (es)
MX (1) MX2019007411A (es)
TW (1) TWI778000B (es)
WO (1) WO2018114878A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210081A (es) 2018-07-13 2021-06-24 Genmab As Variantes de anticuerpos anti-cd38 y sus usos.
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
EP3863673A4 (en) * 2018-10-11 2023-01-11 Momenta Pharmaceuticals, Inc. TREATMENT WITH HIGHLY SIALYLATED IGG COMPOSITIONS
CA3165660A1 (en) 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
MX2022010826A (es) * 2020-03-05 2022-12-02 Momenta Pharmaceuticals Inc Métodos para elaborar inmunoglobulina hipersialilada.
PE20240883A1 (es) 2021-09-06 2024-04-24 Genmab As Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1992016640A1 (en) 1991-03-18 1992-10-01 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU5874798A (en) 1997-01-31 1998-08-25 Biovation Limited Vaccination methods and molecules
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2614046C (en) * 2005-06-30 2018-05-15 Centocor, Inc. Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
EP2435473B1 (en) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
ES2538819T3 (es) * 2009-07-30 2015-06-24 F. Hoffmann-La Roche Ag Procesamiento enzimático de anticuerpos
ES2534936T3 (es) * 2010-08-02 2015-04-30 Ratiopharm Gmbh Método para producir y purificar una sialiltransferasa soluble activa
WO2015123754A1 (en) * 2014-02-18 2015-08-27 The University Of Manitoba Methods to produce single glycoform antibodies
CN106687481B (zh) 2014-09-10 2022-03-22 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体

Also Published As

Publication number Publication date
CN110100007A (zh) 2019-08-06
CA3043158A1 (en) 2018-06-28
TWI778000B (zh) 2022-09-21
JP2020501576A (ja) 2020-01-23
KR102390246B1 (ko) 2022-04-22
US20200165321A1 (en) 2020-05-28
WO2018114878A1 (en) 2018-06-28
EP3559250A1 (en) 2019-10-30
AU2017381656B2 (en) 2020-07-02
TW201835332A (zh) 2018-10-01
AU2017381656A1 (en) 2019-05-23
KR20190084313A (ko) 2019-07-16
JP6931058B2 (ja) 2021-09-01
CN110100007B (zh) 2024-05-28
BR112019009839A2 (pt) 2019-09-17
IL267349A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2019007411A (es) Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
MX2023009109A (es) Una variante de isopropilmalato sintasa novedosa y un procedimiento de produccion de l-leucina usando la misma.
MX2019006266A (es) Glucomanipulacion in vitro de anticuerpos.
AR085302A1 (es) Metodo de produccion de anticuerpos sialilados
EP4249221A3 (en) Double diaphragm shaping of composite materials, assemblies for such shaping, and resulting composite materials
BR112016009365A2 (pt) Método para aumentar, melhorar e estender a produção de etanol e método para diminuir as concentrações finais de dp2 em um produto de fermentação
MX2019006123A (es) Metodo para glicomanipulacion in vitro de anticuerpos.
PH12020500115A1 (en) cAMP RECEPTOR PROTEIN VARIANT AND METHOD OF PRODUCING L-AMINO ACID USING THE SAME
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
EP3415628A4 (en) RECOMBINANT MUTANT MICROORGANISM HAVING MALONIC ACID PRODUCTION CAPACITY AND PROCESS FOR PRODUCING MALONIC ACID USING THE SAME
WO2014125377A3 (en) Highly galactosylated anti-her2 antibodies and uses thereof
WO2019027173A3 (ko) 신규한 싸이코스-6-인산 탈인산효소, 상기 효소를 포함하는 사이코스 생산용 조성물, 상기 효소를 이용하여 사이코스를 제조하는 방법
PH12020550976A1 (en) Camp receptor protein variant and method of producing l-amino acid using the same
UY37398A (es) Proceso para la producción de un ácido orgánico a partir de un material de partida lignocelulósico
PH12019500096A1 (en) Leuconostoc mesenteroides cjlm119 strain producing reduced amount of gas, and kimchi production method using same
ZA202205485B (en) L-methionine producing microorganism to which protein encoded by foreign metz gene is introduced and method for producing l-methionine using same
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
SG11201806843UA (en) Method for producing activated hepatocyte growth factor (hgf)
MY195698A (en) Fermented Soybean Composition and Method for Producing Fermented Soybean Composition
WO2018207184A3 (en) Methods of purifying antibodies
EP4026822A4 (en) METHOD AND SYSTEM FOR PRODUCING METHANE
MX2021014594A (es) Procedimiento de una etapa para producir un oleogel proteico.
MX2016016075A (es) Metodo y composicion para mejorar la productividad de plantas no leguminosas.
SG11202100028PA (en) METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY
IN2014DE03067A (es)